

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VIII LLC, Petitioner

v.

TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,

Patent Owner, based on Electronic Records of PTO

U.S. Patent 7,932,268 to Rader

Filing Date: March 7, 2005

Issue Date: April 26, 2011

TITLE: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED
WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING
SIDE EFFECTS


Inter Partes Review No.: TBD

**Declaration of Randall M. Zusman, M.D. in Support of
Coalition for Affordable Drugs' Petition
for *Inter Partes* Review of U.S. Patent No. 7,932,268**


TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	MY EXPERIENCE AND QUALIFICATIONS	1
III.	SUMMARY OF OPINIONS.....	4
IV.	LIST OF MATERIALS CONSIDERED.....	8
V.	PERSON OF ORDINARY SKILL IN THE ART	8
VI.	BACKGROUND.....	11
A.	Drug development—the cardiologist’s general perspective	11
B.	Cardiovascular disease—non-surgical treatment options and targets available by March 2004	15
1.	Fibrates.....	16
2.	Niacin.....	17
3.	Statins.....	18
4.	Patient populations requiring more than just a statin drug.....	19
5.	MTP Inhibitors.....	21
6.	MTP Inhibitors: Animal and Human Studies	22
7.	MTP Inhibitors: specific dosing considerations.....	24
VII.	THE 268 PATENT	30
A.	The 268 Patent File History.....	31
B.	The 915 Provisional Does Not Support the Claimed Escalating Dose Titration Regimen	34
C.	The Meaning of Certain 268 Patent Claim Terms	42
VIII.	COMPARISON BETWEEN THE 268 PATENT CLAIMS AND THE PRIOR ART.....	44
A.	Disclosures, Knowledge and Information Available in the Art	44
1.	Chang.....	45
2.	Stein 2004.....	47

Declaration of Randall M. Zusman, M.D.
 Petition for *Inter Partes* Review of U.S. Patent No. 7,932,268

3.	The Pink Sheet	50
B.	The Legal Parameters of Obviousness.....	52
C.	Obviousness of the 268 Patent Claims: Pink Sheet in view of Chang.....	55
1.	Subject matter claimed by the 268 Patent claim 1 would have been obvious to the person of ordinary skill.....	57
(a)	“A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising . . .”	58
(b)	“Administering to the subject an effective amount of an MTP inhibitor . . .”	59
(c)	“Wherein said administration comprises at least three step-wise, increasing dose levels of the MTP inhibitors . . .”	60
(d)	“Wherein a first dose level is from about 2 to about 13 mg/day, a second dose level is from about 5 to about 30 mg/day, and a third dose level is from about 10 to about 50 mg/day . . .”	60
(e)	“Wherein the MTP inhibitor is represented by:  or a pharmaceutically acceptable salt thereof or the piperidine N-oxide thereof . . .”	61
(f)	“Wherein each dose level is administered to the subject for about 1 to about 4 weeks.”	62
(g)	The ordinarily skilled artisan would be motivated to combine the Pink Sheet with Chang	64
(h)	The ordinarily skilled artisan would have a reasonable expectation of success	69
2.	268 Patent Claim 2	70
3.	268 Patent Claim 3	72

Declaration of Randall M. Zusman, M.D.
 Petition for *Inter Partes* Review of U.S. Patent No. 7,932,268

4.	268 Patent Claim 4	74
5.	268 Patent Claim 5	75
6.	268 Patent Claim 6	76
7.	268 Patent Claim 7	77
8.	268 Patent Claim 8	78
D.	Obviousness of 268 Patent Claims: Stein 2004 in view of Chang	79
1.	Subject matter claimed by the 268 Patent claim 1 would have been obvious to the person of ordinary skill	81
(a)	“A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising . . .”	82
(b)	“Administering to the subject an effective amount of an MTP inhibitor . . .”	83
(c)	“Wherein said administration comprises at least three step-wise, increasing dose levels of the MTP inhibitors . . .”	84
(d)	“Wherein a first dose level is from about 2 to about 13 mg/day, a second dose level is from about 5 to about 30 mg/day, and a third dose level is from about 10 to about 50 mg/day . . .”	85
(e)	“Wherein the MTP inhibitor is represented by:  or a pharmaceutically acceptable salt thereof or the piperidine N-oxide thereof . . .”	86
(f)	“Wherein each dose level is administered to the subject for about 1 to about 4 weeks.”	86
(g)	The ordinarily skilled artisan would be motivated to combine Stein 2004 with Chang	88
(h)	The ordinarily skilled artisan would have a	

Declaration of Randall M. Zusman, M.D.
Petition for *Inter Partes* Review of U.S. Patent No. 7,932,268

	reasonable expectation of success	93
2.	268 Patent Claim 2	95
3.	268 Patent Claim 3	98
4.	268 Patent Claim 4	100
5.	268 Patent Claim 5	101
6.	268 Patent Claim 6	102
7.	268 Patent Claim 7	103
8.	268 Patent Claim 8	103
E.	Claim Charts	104
	1. The Pink Sheet in view of Chang	104
	2. Stein 2004 in view of Chang	113
IX.	SECONDARY CONSIDERATIONS	122
	A. No Unexpected Results	123
	B. No Failure of Others	124
	C. No Skepticism in the Art	125
X.	CONCLUSION	126

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.